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Background: Stereotactic body radiotherapy (SBRT) has emerged as an effective treatment for localized
prostate cancer. The purpose of this study was to compare the prostate-speciﬁc antigen (PSA) kinetics
between conventionally fractionated external beam radiotherapy (CF-EBRT) and SBRT boost after whole
pelvis EBRT (WP-EBRT) in localized prostate cancer.
Methods: A total of 77 patients with localized prostate cancer [T-stage, T1eT3; Gleason score (GS) 5
e9; PSA < 20 ng/mL] were enrolled. A total of 35 patients were treated with SBRT boost (21 Gy in 3
fractions) after WP-EBRT and 42 patients were treated with CF-EBRT (45 Gy WP-EBRT and boost of
25.2e30.6 Gy in 1.8-Gy fractions). PSA nadir and rate of change in PSA (slope) were calculated and
compared.
Results: With a median follow-up of 52.4 months (range, 14e74 months), the median PSA nadir and
slope for SBRT boost were 0.29 ng/mL and 0.506, 0.235, 0.129, and 0.092 ng/mL/mo, respectively,
for durations of 1 year, 2 years, 3 years, and 4 years postradiotherapy. Similarly, for CF-EBRT, the median
PSA nadir and slopes were 0.39 ng/mL and 0.720 ng/mL/mo, 0.204 ng/mL/mo, 0.121 ng/mL/mo,
and 0.067 ng/mL/mo, respectively. The slope of CF-EBRT was signiﬁcantly different with a greater
median rate of change for 1 year postradiotherapy than that of SBRT boost (P ¼ 0.018). Contrastively, the
slopes of SBRT boost for durations of 2 years, 3 years, and 4 years tended to be continuously greater than
that of CF-EBRT. The signiﬁcantly lower PSA nadir was observed in SBRT boost (median nadir 0.29 ng/mL)
compared with CF-EBRT (median nadir 0.35 ng/mL, P ¼ 0.025). Five-year biochemical failure (BCF) free
survival was 94.3% for SBRT boost and 78.6% for CF-EBRT (P ¼ 0.012).
Conclusion: Patients treated with SBRT boost after WP-EBRT experienced a lower PSA nadir and there
tended to be a continuously greater rate of decline of PSA for durations of 2 years, 3 years, and 4 years
than with CF-EBRT. The improved PSA kinetics of SBRT boost over CF-EBRT led to favorable BCF free
survival.
Copyright © 2015 Asian Paciﬁc Prostate Society, Published by Elsevier. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Prostate cancer is the most common cancer and the second
leading cause of death among men in the United States1 and the
incidence rates in Korea are relatively lower than those in western
nations. However, they continue to increase annually owing to theOncology, Inha University
n, 400-711, South Korea.
im).
ciﬁc Prostate Society, Published baging of society, adoption of westernized lifestyle, and addition of
the prostate-speciﬁc antigen (PSA) screening test to the National
Cancer Screening Program.2 As the prevalence of prostate cancer
increases, various treatment modalities are considered. External
beam radiotherapy (EBRT) is a conventional treatment option for
localized prostate cancer.3
Accumulating recent clinical evidence has demonstrated that
that the a/b ratio of prostate cancer is around 2 Gy and lower than
that of the surrounding normal tissue.4,5 The hypofractionated
radiotherapy schema may improve the biochemical control of
prostate cancer without increasing toxicities associated with late-y Elsevier. This is an open access article under the CC BY-NC-ND license (http://
Table 1
Patient characteristics (n ¼ 77).
Variables SBRT boost (n ¼ 35) CF-EBRT (n ¼ 42) P
Mean age (range) 69.4 (60e78) 71.1 (61e79) 0.212
ECOG scale 0.566
0 22 (62.9%) 28 (66.7%)
1 12 (37.1%) 14 (33.3%)
T stage 0.257
T1eT2a 2 (5.7%) 7 (16.7%)
T2beT2c 29 (82.9%) 34 (80.9%)
T3a 4 (11.4%) 1 (2.4%)
GS 0.087
 6 6 (17.2%) 15 (35.7%)
7 25 (71.4%) 19 (45.2%)
 8 4 (11.4%) 8 (19.1%)
Pretreatment PSA (ng/mL)
Mean (range) 9.06 (4.46e19.50) 10.64 (5.34e18.70) 0.711
< 10 26 (74.3%) 23 (54.8%)
 10 9 (25.7%) 19 (45.2%)
NCCN risk group 0.705
Low 0 (0%) 6 (14.3%)
Intermediate 31 (88.6%) 29 (69.0%)
High 4 (11.4%) 7 (16.7%)
CF-EBRT, conventionally fractionated external beam radiotherapy; ECOG scale,
Eastern Cooperative Oncology Group performance scale; GS, Gleason score; NCCN,
National Comprehensive Cancer Network; PSA, prostate-speciﬁc antigen; SBRT,
stereotactic body radiotherapy.
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radiotherapy (SBRT) boost after EBRT has demonstrated excellent
efﬁcacy and toxicity proﬁles.6,7
The PSA test is the most common initial test for men who are
worried about prostate cancer.8 However, PSA is a well-
established biomarker for prostate cancer and available for
monitoring response to treatment. In patients without androgen
deprivation therapy (ADT), analysis of PSA kinetics after treat-
ment could reveal the biologic effect of radiation on prostate
cancer. The changes of PSA after radical prostatectomy, EBRT, and
brachytherapy have been extensively researched.9 Lower PSA
nadir and rapid decline in PSA after treatment have been related
to improved clinical outcome.10e13 While recent studies have
demonstrated that a lower PSA nadir (< 0.5 ng/mL) has been
associated with superior clinical disease free survival,13,14 the
interpretation of the decline rate of PSA following radiotherapy is
controversial. Some reports have shown a positive relationship
between the increase of the decline rate and clinical outcome,
while others have been negative.15e19 Furthermore, kinetics of
PSA decline following SBRT using Cyberknife remains poorly
understood and there are only a few reports from western
countries.20,21 It is necessary to elucidate the kinetics of SBRT
in Asian populations. The objective of this study is to compare
the PSA kinetics (nadir and rate of decline of PSA) of hypo-
fractionated SBRT boost after whole pelvis EBRT (WP-EBRT) with
conventionally fractionated EBRT (CF-EBRT) in localized
prostate cancer.2. Materials and methods
2.1. Patient characteristics
From 2008 to 2014, 35 patients newly diagnosed with local-
ized prostate cancer who were treated with SBRT boost after WP-
EBRT using the Cyberknife robotic radiosurgery system (Accurray
Incorporated, Sunnyvale, CA, USA) were enrolled in this retro-
spective analysis. All patients had histologically conﬁrmed pri-
mary adenocarcinoma of the prostate. None of these patients had
received any other local or systemic primary treatment of pros-
tate cancer. Prior transurethral resection of the prostate for uri-
nary symptom relief was allowed. Patients were stratiﬁed
according to 2.2014 NCCN risk stratiﬁcation guidelines.22 The
study was approved by the Ethical Committee for Clinical Trials of
our institution and the retrospective data was prospectively
collected in our institutional database. In order to have a ho-
mogenous initial PSA level in this group, we excluded patients
whose initial PSA level was above 20 ng/mL in high-risk prostate
cancer patients. In order to assess PSA kinetics in response to
radiotherapy alone, we stopped follow-up on the PSA evaluation
if they failed therapy by Phoenix deﬁnition.23 PSA values taken
after the start of ADT were excluded. All included patients had at
least 1 year of follow-up. PSA bounce was deﬁned as an absolute
increase of 0.2 ng/mL from the previous PSA level, followed by a
subsequent decrease.24 Toxicity was documented at follow-up
visits using the Radiation Therapy Oncology Groups scale. To
compare the cohort of patients treated with CF-EBRT, the records
from a prospectively collected cohort of patients treated at our
institute from 2006 through 2012 were reviewed. We identiﬁed
42 patients treated with CF-EBRT who met the above inclusion
criteria. All patients treated with CF-EBRT alone received doses
between 70.2 Gy and 75.6 Gy. A comparison between the two
radiotherapy cohorts of patient baseline characteristics is shown
in Table 1.2.2. Whole pelvis radiotherapy and SBRT boost treatment planning
and delivery
Four or more gold ﬁducial markers were implanted trans-
perineally into the prostate. After 7 days, patients underwent MR
imaging and thin-cut CT scan. Fused CT and MR images were used
for the treatment planning. The prostate, seminal vesicles, rectum,
bladder, penile bulb, and bowel were contoured. The prostate
gland, the seminal vesicles, and the area of radiographic extrac-
apsular extension were deﬁned as the clinical target volume
(CTV1). CTV2 included the external iliac nodes, the internal iliac
nodes, the presacral nodes, and the obturator nodes. The planning
target volume (PTV1) was extended 7 mm beyond the CTV1 in all
directions, except in the posterior direction, wherein it was
extended 5mm. The PTV2was extended 7mm in all directions. The
prescription dose of WPRT was 45 Gy and was administered in 25
fractions. A minimum of 95% of the prescription dose was assured
to cover 100% of the PTV. All WPRT treatment plans were generated
on Varian Eclipse treatment planning system (version 8.8.6, Varian
Medical Systems, Palo Alto, CA, USA).
In SBRT boost planning, the prostate gland, the seminal vesicles,
and the area of radiographic extracapsular extension were deﬁned
as the CTV which was the same as that of the WPRT treatment
plans. The PTV extended 5 mm beyond the CTV in all directions,
except in the posterior direction, wherein it was extended 3 mm.
The prescription boost dose of 21 Gy, delivered in three fractions,
was prescribed to the PTV. The prescription dose covered at least
95% of the PTV, normalized to the 75e85% isodose line [mean ho-
mogeneity index of 1.31 (range, 1.21e1.41)]. The rectal dose-volume
goals were < 50% of the rectal volume receiving 50% of the pre-
scribed dose, < 20% receiving 80% of the dose, < 10% receiving 90%
dose, and < 5% receiving 100% of the dose. Treatments were given
over 3 consecutive days.2.3. CF-EBRT treatment planning and delivery
The CTV included the prostate, seminal vesicles, and internal
iliac, external iliac, and obturator nodal regions. The upper limit of
the CTV was the level of the common iliac bifurcation, which was
Table 2
Comparison of the rate of prostate-speciﬁc antigen (PSA) decline of stereotactic body
radiotherapy (SBRT) boost and conventionally fractionated external beam radio-
therapy (CF-EBRT).
Through year SBRT boost CF-EBRT P
0e1 0.506 0.720 0.018
0e2 0.235 0.204 0.051
0e3 0.129 0.121 0.799
0e4 0.092 0.067 0.375
Phak et al / PSA kinetics of SBRT boost vs. WPRT 27generally located at or just above the L5/S1 junction. The PTV was a
5e7 mm expansion of the CTV. The prescription dose of WPRT was
45 Gy and was administered in 25 fractions. A minimum of 95% of
the prescription dose was assured to cover 100% of the PTV. After
pelvic radiotherapy, the boost treatment included only the prostate
and seminal vesicles. The boost dose of 25.2e30.6 Gy in 1.8-Gy
fractions was administered. All CF-EBRT treatment plans were
generated on Varian Eclipse treatment planning system (version
8.8.6, Varian Medical Systems).CF-EBRT, conventionally fractionated external beam radiotherapy; SBRT, stereo-
tactic body radiotherapy.2.4. Statistical analysis
To eliminate the effect of differing follow-up durations between
SBRT boost after EBRT and CF-EBRT, we calculated the rate of
change in PSA over an interval of time from the completion of
radiotherapy to 1 year, 2 years, 3 years, and 4 years posttreatment.
The slope of PSA change (ng/mL/mo) was calculated as the
regression coefﬁcient in a linear regression model for each indi-
vidual.25 The t test was performed to compare mean values and
analysis of variance in continuous variables and the Man-
neWhitney test was used to compare distributions of the slope of
PSA. Biochemical failure (BCF) free survival was estimated using the
KaplaneMeier method. Statistical analysis was performed using
the IBM SPSS software, version 19.0 (SPSS, Inc., IBM, Chicago,
IL, USA).3. Results
All patients completed the treatment. Seventy-seven patients
with a median of 52.4 months (range, 14e74 mo) follow-up were
analyzed. The pretreatment median PSA levels were 9.06 ng/mL
(4.46e19.50 ng/mL) in SBRT boost and 10.64 ng/mL (5.34e18.70 ng/
mL) in CF-EBRT (P ¼ 4.46e19.50; P ¼ 0.711, Table 1).
Fig. 1 shows PSA changes declining over times, with different
rates of PSA decline for each time interval since radiotherapy. To
investigate the PSA kinetics after radiotherapy, the rate of PSA
decline (slope) was calculated for four intervals following radio-
therapy (0e1 year, 0e2 years, 0e3 years, and 0e4 years). The rate of
PSA decline (slope) for the CF-EBRT cohort was maximal in the 1st
year, but tapered off in the following years, with median values
of 0.720 ng/mL/mo, 0.204 ng/mL/mo, 0.121 ng/mL/mo,
and 0.067 ng/mL/mo for durations of 1 year, 2 years, 3 years, andFig. 1. Prostate-speciﬁc antigen changes after stereotactic body radiotherapy (SBRT)
boost after external beam radiotherapy (EBRT) and conventionally fractionated EBRT
(CF-EBRT).4 years postradiotherapy, respectively (Table 2). Similarly, the slope
of PSA for the SBRT boost was maximal in the 1st year with median
values of 0.506 ng/mL/mo, 0.235 ng/mL/mo, 0.129 ng/mL/mo,
and 0.092 ng/mL/mo for durations of 1 year, 2 years, 3 years, and
4 years, respectively. Although the magnitude of the slopes for both
SBRT boost and CF-EBRT decreased with time, the slope of CF-EBRT
was signiﬁcantly different with a greater median rate of change for
1 year postradiotherapy than that of SBRT boost (0.720 ng/mL/mo
for CF-EBRT versus 0.506 ng/mL/mo for SBRT boost, P ¼ 0.018).
Contrastively, the slopes of SBRT boost for durations of 2 years,
3 years, and 4 years tended to be continuously greater than that of
CF-EBRT (0.235 ng/mL/mo,0.129 ng/mL/mo, and0.092 ng/mL/
mo, respectively, for SBRT boost versus 0.204 ng/mL/
mo, 0.121 ng/mL/mo, and 0.067 ng/mL/mo for CF-EBRT),
although there were no statistical signiﬁcances. Because the in-
clusion criteria make this a relatively homogenous population,
there were no signiﬁcant differences in the comparison of the rate
of PSA decline by the Gleason score ( 6 vs. 7) and pretreatment
PSA ( 10 vs. > 10).
The PSA response as deﬁned by PSA nadir has been excellent.
The entire cohort has achieved a median 0.35 ng/mL (range,
0.04e1.44 ng/mL). The SBRT boost cohort achieved a median PSA
nadir of 0.29 ng/mL (range, 0.04e1.44 ng/mL) with a median
follow-up of 32.3 months and the CF-EBRT cohort achieved a me-
dian PSA nadir of 0.39 ng/mL (range, 0.04e1.82 ng/mL) with a
median follow-up of 25.2 months (Fig. 2 and Table 3). The signiﬁ-
cantly lower PSA nadir was observed in the SBRT boost cohort
(P ¼ 0.025) and the time to PSA nadir was statistically longer for
SBRT boost when compared to CF-EBRT (P ¼ 0.043). Benign PSAFig. 2. The graph shows prostate-speciﬁc antigen (PSA) nadir after stereotactic body
radiotherapy (SBRT) boost after external beam radiotherapy (EBRT) and conventionally
fractionated EBRT (CF-EBRT).
Table 3
PSA kinetics of SBRT boost and CF-EBRT.
SBRT boost CF-EBRT P
Median PSA
nadir
0.29 ng/mL (0.04e1.44) 0.39 ng/mL (0.04e1.82) 0.025
PSA nadir 
0.5 ng/mL
29 (82.9%) 25 (59.5%) 0.008
Median time
to nadir
32.3 mo (12e51) 25.2 months (9e58) 0.043
PSA bounce 10 (28.6%) 9 (21.4%) 0.837
Median height
of PSA bounce
0.28 ng/mL (0.21e0.58) 0.38 ng/mL (0.22e1.20) 0.222
Median time to
bounce
11.6 mo (6e25) 16.0 mo (6e30) 0.388
CF-EBRT, conventionally fractionated external beam radiotherapy; PSA, prostate-
speciﬁc antigen; SBRT, stereotactic body radiotherapy.
Table 4
Acute and late genitourinary and gastrointestinal toxicity of stereotactic body
radiosurgery boost.
Variables SBRT boost (%) CF-EBRT (%) P
Acute GU Grade 1 48.6% 42.9% 0.852
Grade 2 22.9% 38.1% 0.254
Acute GI Grade 1 28.6% 40.4% 0.086
Grade 2 20.0% 16.7% 0.586
Late GU Grade 1 14.2% 11.9% 0.632
Grade 2 8.6% 9.5% 0.256
Late GI Grade 1 20.0% 14.3% 0.097
Grade 2 11.4% 11.9% 0.152
Grade 3 0.0% 2.3% 0.098
CF-EBRT, conventionally fractionated external beam radiotherapy; GI, gastrointes-
tinal; GU, genitourinary; SBRT, stereotactic body radiotherapy.
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PSA bounce was more frequent in patients treated with SBRT boost
compared to CF-EBRT (28.6% vs. 21.4%, P ¼ 0.837), but there was no
statistical signiﬁcance. Patients with PSA bounces had lower pre-
treatment PSA levels (10.66 ng/mL vs. 7.68 ng/mL, P ¼ 0.014) and
were associated with a low-risk group (P ¼ 0.001).
BCF were observed in two patients with SBRT boost and nine
patients with CF-EBRT. The actuarial 5-year BCF free survival was
94.3% for patients treated with SBRT boost and 78.6% for CF-EBRT
(P ¼ 0.012, Fig. 3).
The frequency of toxicity events divided by treatment type is
presented in Table 4. The prevalent acute toxicities after radio-
therapy were urinary frequency and rectal pain but usually
resolved within 1e2 months on basic symptomatic therapy. The
difference in acute toxicity between SBRT boost and CF-EBRT was
not statistically signiﬁcant. The rates of late Grade 1e2 genitouri-
nary (GU) and gastrointestinal (GI) toxicities were similar in both
groups. There was only one Grade 3 late GI toxicity event in the CF-
EBRTgroup. One patient in the CF-EBRTgroup complained of severe
hematochezia and bowel habit change, which was surgically
managed.
4. Discussion
In this report, we described the changes in the PSA levels in
patients with localized prostate cancer treated with SBRT boostFig. 3. Biochemical failure free survival after stereotactic body radiotherapy (SBRT)
boost and conventionally fractionated external beam radiotherapy (CF-EBRT).after WP-EBRT and CF-EBRT without ADT. The majority of PSA de-
clines occurred in the 1st year but tapered off quickly in the
following years at both treatmentmodalities. Several reports in PSA
kinetics have shown that signiﬁcant PSA change occurs in the 1st
year following radiotherapy.26,27 Consistently, in our study, the
majority of the PSA decline occurred in the 1st year. Although the
decline rate of PSA in CF-EBRT was greater through Year 1, the
decline rate for SBRT boost did not fall off as quickly as CF-EBRT
during 1 year, but declined consistently more rapidly for a dura-
tion of 2 years, 3 years, and 4 years than that of CF-EBRT.
Shi et al25 reported that a rapid PSA decline in the 1st year
following EBRT is positively associated with prostate cancer-
speciﬁc mortality. Katz et al28 demonstrated that PSA declines
steadily after treatment and achieves very low mean levels of
0.25 ng/mL within 4e5 years. Anwar et al20 reported that the PSA
slope for SBRT was greater than for CF-EBRT (P < 0.05) at 2 and
3 years following radiotherapy. This was consistent with our re-
sults. A moderate PSA decline of SBRT boost in the 1st year, which is
a slower decline compared with that of CF-EBRT, and a steady
decline for a duration of 2 years, 3 years, and 4 years resulted in
lower PSA nadirs than that of CF-EBRT. A lower PSA nadir and a not
rapid but steady PSA decline might lead to favorable BCF free sur-
vival in SBRT boost.
Anwar et al20 compared the PSA kinetics between hypofractio-
nated SBRT and CF-EBRT for localized prostate cancer and reported
that the median slopes for SBRT were 0.09 ng/mL/mo, 0.06 ng/
mL/mo, and 0.05 ng/mL/mo, respectively, for durations of 1 year,
2 years, and 3 years postradiotherapy. In our study, the rate of PSA
decline after SBRT boost combined with WP-EBRT was 0.506 ng/
mL/mo, 0.235 ng/mL/mo, 0.129 ng/mL/mo, and 0.092 ng/mL/
mo for durations of 1 year, 2 years, 3 years, and 4 years, respectively.
Although the direct comparison of rates of PSA decline with other
studies is not proper, the rate of PSA decline in our study tends to be
more rapid, but the pretreatment PSA level of 9.06 ng/mL in our
study was slightly higher than 6.2 ng/mL in the report of Anwar
et al.20 Shi et al25 described that a lower PSA at diagnosis had a
lower PSA velocity following radiotherapy. High pretreatment
median PSA might inﬂuence the slope of PSA decline. However, the
difference in rate of PSA decline after radiotherapy may, due to
underlying biologic differences between Asian and Western men,
but any racial differences in PSA kinetics after hypofractionated
radiotherapy, need further studies.
Recent clinical evidence has demonstrated that the a/b ratio of
prostate cancer may be around 2 Gy.4,5 SBRT boost (3 fractions of
7 Gy) after WP-EBRT (25 fractions of 1.8 Gy) delivered a Biologic
Equivalent Dose (BED) of 180 Gy, assuming an a/b ratio of 2 (e.g.,
BED2), compared with a BED2 of 133.4e143.6 Gy with CF-EBRT
(39e42 fractions of 1.8 Gy). Consistent with dose escalation trials
which have shown a lower PSA nadir with increased total dose,29
Phak et al / PSA kinetics of SBRT boost vs. WPRT 29we expect the SBRT boost after WP-EBRT regimen to produce a
lower PSA nadir and a continuative decline of PSA. In our study, the
PSA decline of SBRT boost was not signiﬁcantly notable in the 1st
year, but constantly decreased during periods of 2 years, 3 years,
and 4 years to achieve lower PSA nadir than that of CF-EBRT. Lamb
et al30 showed that the postradiation nadir PSA is the strongest
indicator. Zelefsky et al31 demonstrated that nadir PSA values of
 1.5 ng/mL at 2 years after radiation therapy for prostate cancer
predict for long-term distant metastases and cause-speciﬁc mor-
tality. We regard the low nadir of 0.29 ng/mL in SBRT boost after
WP-EBRT as indicative of a favorable outcome. Constant declines of
PSA for durations of 1 year, 2 years, 3 years, and 4 years and lower
PSA nadirs led to favorable BCF free survival, despite the limited
follow-up.
Lin et al32 reported results on toxicity using WBRT and SBRT
boost for high-risk prostate cancer. During radiotherapy, 27% of
patients had Grade 2 GU toxicity, 12% had Grade 2 acute GI toxicity,
therewas no Grade 3 acute toxicity noted, and therewas no Grade 3
late GU and GI toxicity at last follow-up.
Our study is limited by the retrospective nature of the analysis
and the small number of patients. Therewere no strict protocols for
the clinical decision-making process. Future studies should employ
more comprehensive instruments to assess the effect of prostate
SBRT.
In this report of localized prostate cancer, a continuously greater
rate of decline in PSA for durations of 2 years, 3 years, and 4 years
following SBRT boost after WP-EBRT resulted in lower PSA nadirs
compared with CF-EBRT. The improved PSA kinetics of SBRT boost
over CF-EBRT led to favorable BCF free survival. Although follow-up
of SBRT boost is limited due to its recent start in the clinic, the
improved PSA kinetics of SBRT boost over CF-EBRT are promising
for control of prostate cancer.
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